These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

645 related articles for article (PubMed ID: 34122422)

  • 1. Immune Checkpoint Inhibitor-Associated Pneumonitis in Non-Small Cell Lung Cancer: Current Understanding in Characteristics, Diagnosis, and Management.
    Zhang Q; Tang L; Zhou Y; He W; Li W
    Front Immunol; 2021; 12():663986. PubMed ID: 34122422
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immune-related adverse events of a PD-L1 inhibitor plus chemotherapy versus a PD-L1 inhibitor alone in first-line treatment for advanced non-small cell lung cancer: A meta-analysis of randomized control trials.
    Wang M; Liang H; Wang W; Zhao S; Cai X; Zhao Y; Li C; Cheng B; Xiong S; Li J; He J; Liang W
    Cancer; 2021 Mar; 127(5):777-786. PubMed ID: 33119182
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comprehensive Analysis of the Immune Microenvironment in Checkpoint Inhibitor Pneumonitis.
    Lin X; Deng J; Deng H; Yang Y; Sun N; Zhou M; Qin Y; Xie X; Li S; Zhong N; Song Y; Zhou C
    Front Immunol; 2021; 12():818492. PubMed ID: 35095920
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tumor invasion in the central airway is a risk factor for early-onset checkpoint inhibitor pneumonitis in patients with non-small cell lung cancer.
    Moda M; Saito H; Kato T; Usui R; Kondo T; Nakahara Y; Murakami S; Yamamoto K; Yamada K
    Thorac Cancer; 2020 Dec; 11(12):3576-3584. PubMed ID: 33078531
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The association between the incidence risk of pneumonitis and PD-1/PD-L1 inhibitors in advanced NSCLC: A meta-analysis of randomized controlled trials.
    Lin GF; Xu Y; Lin H; Yang DY; Chen L; Huang LL; Su XS; Xu YX; Zeng YM
    Int Immunopharmacol; 2021 Oct; 99():108011. PubMed ID: 34426108
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Real-world incidence and impact of pneumonitis in patients with lung cancer treated with immune checkpoint inhibitors: a multi-institutional cohort study.
    Tiu BC; Zubiri L; Iheke J; Pahalyants V; Theodosakis N; Ugwu-Dike P; Seo J; Tang K; Sise ME; Sullivan R; Naidoo J; Mooradian MJ; Semenov YR; Reynolds KL
    J Immunother Cancer; 2022 Jun; 10(6):. PubMed ID: 35705313
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Checkpoint Inhibitor Pneumonitis Induced by Anti-PD-1/PD-L1 Therapy in Non-Small-Cell Lung Cancer: Occurrence and Mechanism.
    Yin J; Wu Y; Yang X; Gan L; Xue J
    Front Immunol; 2022; 13():830631. PubMed ID: 35464480
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Programmed cell death 1 (PD-1)/PD-ligand 1(PD-L1) inhibitors-related pneumonitis in patients with advanced non-small cell lung cancer.
    Sun Y; Shao C; Li S; Xu Y; Xu K; Zhang Y; Huang H; Wang M; Xu Z
    Asia Pac J Clin Oncol; 2020 Dec; 16(6):299-304. PubMed ID: 32757454
    [TBL] [Abstract][Full Text] [Related]  

  • 9. High mortality and poor treatment efficacy of immune checkpoint inhibitors in patients with severe grade checkpoint inhibitor pneumonitis in non-small cell lung cancer.
    Tone M; Izumo T; Awano N; Kuse N; Inomata M; Jo T; Yoshimura H; Minami J; Takada K; Miyamoto S; Kunitoh H
    Thorac Cancer; 2019 Oct; 10(10):2006-2012. PubMed ID: 31482678
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immune-related pulmonary toxicities of checkpoint inhibitors in non-small cell lung cancer: Diagnosis, mechanism, and treatment strategies.
    Guo X; Chen S; Wang X; Liu X
    Front Immunol; 2023; 14():1138483. PubMed ID: 37081866
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immune Checkpoint Inhibitor-Associated Colitis: From Mechanism to Management.
    Tang L; Wang J; Lin N; Zhou Y; He W; Liu J; Ma X
    Front Immunol; 2021; 12():800879. PubMed ID: 34992611
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immunotherapy Alone or in Combination with Chemotherapy as First-Line Treatment of Non-Small Cell Lung Cancer.
    Saxena P; Singh PK; Malik PS; Singh N
    Curr Treat Options Oncol; 2020 Jul; 21(8):69. PubMed ID: 32720019
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Radiographic features and prognosis of early- and late-onset non-small cell lung cancer immune checkpoint inhibitor-related pneumonitis.
    Huang A; Xu Y; Zang X; Wu C; Gao J; Sun X; Xie M; Ma X; Deng H; Song J; Ren F; Pang L; Qian J; Yu Z; Wan S; Chen Y; Pan L; Zhuang G; Liu S; Xue X
    BMC Cancer; 2021 May; 21(1):634. PubMed ID: 34051746
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pneumonitis in Non-Small Cell Lung Cancer Patients Receiving Immune Checkpoint Immunotherapy: Incidence and Risk Factors.
    Suresh K; Voong KR; Shankar B; Forde PM; Ettinger DS; Marrone KA; Kelly RJ; Hann CL; Levy B; Feliciano JL; Brahmer JR; Feller-Kopman D; Lerner AD; Lee H; Yarmus L; D'Alessio F; Hales RK; Lin CT; Psoter KJ; Danoff SK; Naidoo J
    J Thorac Oncol; 2018 Dec; 13(12):1930-1939. PubMed ID: 30267842
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Anti‑PD‑1/PD‑L1 and anti‑CTLA‑4 associated checkpoint inhibitor pneumonitis in non‑small cell lung cancer: Occurrence, pathogenesis and risk factors (Review).
    Hu X; Ren J; Xue Q; Luan R; Ding D; Tan J; Su X; Yang J
    Int J Oncol; 2023 Nov; 63(5):. PubMed ID: 37681488
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Risk Factors for Immune Checkpoint Inhibitor-Related Pneumonitis in Cancer Patients: A Systemic Review and Meta-Analysis.
    Zhou P; Zhao X; Wang G
    Respiration; 2022; 101(11):1035-1050. PubMed ID: 36108598
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Safety of current immune checkpoint inhibitors in non-small cell lung cancer.
    Abdayem P; Planchard D
    Expert Opin Drug Saf; 2021 Jun; 20(6):651-667. PubMed ID: 33393387
    [No Abstract]   [Full Text] [Related]  

  • 18. Outcome and risk factor of immune-related adverse events and pneumonitis in patients with advanced or postoperative recurrent non-small cell lung cancer treated with immune checkpoint inhibitors.
    Isono T; Kagiyama N; Takano K; Hosoda C; Nishida T; Kawate E; Kobayashi Y; Ishiguro T; Takaku Y; Kurashima K; Yanagisawa T; Takayanagi N
    Thorac Cancer; 2021 Jan; 12(2):153-164. PubMed ID: 33201587
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The predict factors and clinical prognosis value of immune-related pneumonia of receiving PD-1 inhibitor in advanced non-small cell lung cancer: A retrospective study.
    Yang J; Lyu M; Feng X; Liu F; Zeng R; Sun X; Bao Z; Zhou L; Gao B; Ni L; Xiang Y
    Int Immunopharmacol; 2024 Dec; 142(Pt B):113140. PubMed ID: 39312858
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Case report: Pneumonia with clinical symptoms precedes imaging evidence after immune checkpoint inhibitors combined with radiotherapy in lung squamous cell cancer.
    Wang Y; Wang Y; Yu J; Meng X
    Front Immunol; 2022; 13():998516. PubMed ID: 36189237
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 33.